Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Selling-General-and-Administrative" stands at 6.98 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Amgen Inc's third quarter result of 1.72 Billion USD for the item "Selling General and Administrative" represents an increase of 1.71 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 1.72 Billion USD for the item "Selling General and Administrative" represents an increase of 5.85 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 6.98 Billion USD for the item "Selling General and Administrative" represents an increase of 1.38 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -6.89 percent compared to the value the year prior.
The 1 year change in percent is -6.89.
The 3 year change in percent is 32.45.
The 5 year change in percent is 27.53.
The 10 year change in percent is 46.65.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Selling General and Administrative | 905,699,262,464.00 |
![]() | Johnson & Johnson - Selling General and Administrative | 486,508,953,600.00 |
![]() | AbbVie Inc - Selling General and Administrative | 399,570,305,024.00 |
![]() | Roche Holding AG - Selling General and Administrative | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Selling General and Administrative | 280,205,508,085.11 |